GDD welcomes factory invested by intl biomedicine giant

Lonza Group is a global leading biomedicine company managing businesses covering various areas such as biological conjugates, cells, and gene therapy. [Photo provided by Lonza Group]

Lonza Group launched the detailed plans for its new factory for the clinical development and manufacturing of mammalian products in China-Singapore Guangzhou Knowledge City (CSGKC), Guangzhou Development District (GDD) in late March.

The factory, covering 17,000 square meters, was listed in the tripartite agreement signed by Lonza Group, Cytiva and GDD in 2018.

Lonza Group is a global leading contract development manufacture organization (CDMO) in biomedicine, covering various areas such as biological conjugates, cells, and gene therapy.

The factory in GDD will be the seventh of its kind for mammalian products manufacturing that Lonza has set up around the world, with the previous six located in the United States, Switzerland, Spain, the United Kingdom and Singapore.

The factory has been designed with a laboratory area of 6,500 sq m and a modular biological drug production unit for GE KUBio.

David Maier, the head of Lonza's project in China, noted that the reason why the group is establishing more businesses in China is the rapid development achieved by the group’s business and China's CDMO in recent years.

Share - WeChat